S. 2658

Status: Reported

Medication Affordability and Patent Integrity Act

Medication Affordability and Patent Integrity Act

Sponsored by Margaret Wood Hassan (Democrat-NH)

Topics

Cosponsors

1

Actions

7

Roll calls

0

Amendments

0

Related bills

0

Actions

Jul 28, 2026 · Library of Congress

Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 28, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 28, 2026 · Senate

Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.

Jun 17, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Mar 19, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Hearings held.

Aug 1, 2025 · Library of Congress

Introduced in Senate

Aug 1, 2025 · Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest activity

2 events unlock with a free account

2 rulemakings this week

Create free account →

July 2026

Lobbying reported · Whitmer & Worrall · Jul 22

Whitmer & Worrall reported 2nd Quarter (Apr 1 - June 30) lobbying for Campaign For Sustainable Drug Pricing (csrxp) — $50,000

BillsH.R. 1262 H.R. 1843 H.R. 3160 H.R. 3269 H.R. 3789 H.R. 4570 H.R. 5526 H.R. 6485 S. 43 S. 1032 S. 1040 S. 1041 S. 1096 S. 1414 S. 1546 S. 1954 S. 2658 S. 3014

Lobbying reported · National Taxpayers Union · Jul 21

National Taxpayers Union reported 2nd Quarter (Apr 1 - June 30) lobbying for National Taxpayers Union — $30,000

Lobbying reported · Viatris · Jul 21

Viatris reported 2nd Quarter (Apr 1 - June 30) lobbying for Viatris — $360,000

BillsS. 891 S. 2296 S. 2658 S. 3778 S. 3841

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Covington & Burling · Jul 20

Covington & Burling reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research Manufacturers Of America — $220,000

BillsH.R. 2715 H.R. 5526 H.R. 7953 H.R. 8646 S. 1414 S. 1954 S. 2658 S. 3014

Lobbying reported · America's Health Insurance Plans (ahip) · Jul 20

America's Health Insurance Plans (ahip) reported 2nd Quarter (Apr 1 - June 30) lobbying for America's Health Insurance Plans (ahip) — $3,010,000

BillsH.R. 1 H.R. 247 H.R. 379 H.R. 584 H.R. 608 H.R. 610 H.R. 842 H.R. 935 H.R. 950 H.R. 957 H.R. 1096 H.R. 1117 H.R. 1157 H.R. 1162 H.R. 1397 H.R. 1403 H.R. 1523 H.R. 1614 H.R. 1627 H.R. 1775 H.R. 1776 H.R. 1805 H.R. 1867 H.R. 1899 H.R. 1924 H.R. 2013 H.R. 2045 H.R. 2049 H.R. 2079 H.R. 2199 H.R. 2309 H.R. 2433 H.R. 2450 H.R. 2528 H.R. 2533 H.R. 2553 H.R. 2554 H.R. 2571 H.R. 2586 H.R. 2610 H.R. 2636 H.R. 2741 H.R. 3000 H.R. 3023 H.R. 3069 H.R. 3415 H.R. 3493 H.R. 3527 H.R. 3546 H.R. 3701 H.R. 3789 H.R. 3808 H.R. 4093 H.R. 4206 H.R. 4231 H.R. 4313 H.R. 4317 H.R. 4406 H.R. 4559 H.R. 4605 H.R. 4623 H.R. 4641 H.R. 4710 H.R. 5081 H.R. 5145 H.R. 5243 H.R. 5281 H.R. 5371 H.R. 5509 H.R. 5526 H.R. 5582 H.R. 5584 H.R. 6010 H.R. 6232 H.R. 6248 H.R. 6255 H.R. 6361 H.R. 6703 H.R. 6951 H.R. 6974 H.R. 7023 H.R. 7064 H.R. 7164 H.R. 7189 H.R. 7409 H.R. 7537 H.R. 7727 H.R. 7778 H.R. 7787 H.R. 7790 H.R. 7803 H.R. 7837 H.R. 7871 H.R. 8270 H.R. 8375 H.R. 8377 H.R. 8684 H.R. 8779 H.R. 8875 H.R. 9393 H.R. 9504 S. 339 S. 483 S. 526 S. 529 S. 652 S. 717 S. 729 S. 752 S. 864 S. 882 S. 891 S. 931 S. 939 S. 976 S. 1040 S. 1041 S. 1056 S. 1082 S. 1096 S. 1227 S. 1261 S. 1414 S. 1637 S. 1753 S. 1816 S. 1818 S. 1847 S. 1954 S. 1973 S. 2237 S. 2289 S. 2345 S. 2355 S. 2356 S. 2497 S. 2556 S. 2620 S. 2658 S. 2709 S. 2903 S. 3014 S. 3599 S. 3642 S. 3690 S. 3727 S. 3729 S. 3750 S. 3751 S. 3762 S. 3822 S. 3829 S. 3834 S. 3848 S. 3886 S. 3990 S. 4189 S. 4332 S. 4355 S. 4384 S. 4509 S. 4512

Lobbying reported · Association for Accessible Medicines · Jul 20

Association for Accessible Medicines reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Accessible Medicines — $870,000

BillsH.R. 3160 H.R. 3269 H.R. 5526 H.R. 5811 H.R. 6485 H.R. 7148 H.R. 8269 H.R. 8339 S. 43 S. 1041 S. 1096 S. 1414 S. 1546 S. 1553 S. 1954 S. 2658 S. 3469 S. 3788

Lobbying reported · The Nickles Group · Jul 20

The Nickles Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $60,000

BillsH.R. 1 S. 1954 S. 2658 S. 3014 S. 3788

Lobbying reported · Blue Cross And Blue Shield Of Florida · Jul 20

Blue Cross And Blue Shield Of Florida reported 2nd Quarter (Apr 1 - June 30) lobbying for Blue Cross And Blue Shield Of Florida — $80,000

Lobbying reported · Chamber Of Commerce Of The U.s.a. · Jul 20

Chamber Of Commerce Of The U.s.a. reported 2nd Quarter (Apr 1 - June 30) lobbying for Chamber Of Commerce Of The U.s.a. — $16,950,000

BillsH.Con.Res. 34 H.J.Res. 35 H.J.Res. 59 H.J.Res. 61 H.J.Res. 64 H.J.Res. 74 H.J.Res. 87 H.J.Res. 88 H.J.Res. 89 H.R. 33 H.R. 77 H.R. 161 H.R. 278 H.R. 448 H.R. 471 H.R. 640 H.R. 755 H.R. 804 H.R. 1013 H.R. 1047 H.R. 1070 H.R. 1109 H.R. 1152 H.R. 1163 H.R. 1190 H.R. 1335 H.R. 1340 H.R. 1343 H.R. 1469 H.R. 1588 H.R. 1665 H.R. 1681 H.R. 1687 H.R. 1721 H.R. 1731 H.R. 1799 H.R. 1897 H.R. 1949 H.R. 2089 H.R. 2145 H.R. 2213 H.R. 2225 H.R. 2289 H.R. 2308 H.R. 2385 H.R. 2467 H.R. 2528 H.R. 2548 H.R. 2612 H.R. 2617 H.R. 2635 H.R. 2651 H.R. 2675 H.R. 2696 H.R. 2709 H.R. 2794 H.R. 2799 H.R. 2804 H.R. 2853 H.R. 2854 H.R. 2940 H.R. 2964 H.R. 2986 H.R. 3015 H.R. 3062 H.R. 3109 H.R. 3209 H.R. 3227 H.R. 3269 H.R. 3301 H.R. 3339 H.R. 3343 H.R. 3351 H.R. 3352 H.R. 3381 H.R. 3382 H.R. 3383 H.R. 3394 H.R. 3446 H.R. 3447 H.R. 3512 H.R. 3552 H.R. 3616 H.R. 3617 H.R. 3628 H.R. 3632 H.R. 3638 H.R. 3645 H.R. 3657 H.R. 3668 H.R. 3673 H.R. 3682 H.R. 3699 H.R. 3862 H.R. 3898 H.R. 3899 H.R. 3959 H.R. 4016 H.R. 4109 H.R. 4121 H.R. 4168 H.R. 4171 H.R. 4213 H.R. 4214 H.R. 4218 H.R. 4357 H.R. 4386 H.R. 4393 H.R. 4409 H.R. 4429 H.R. 4430 H.R. 4431 H.R. 4437 H.R. 4466 H.R. 4478 H.R. 4503 H.R. 4553 H.R. 4661 H.R. 4669 H.R. 4754 H.R. 4767 H.R. 4776 H.R. 4806 H.R. 5077 H.R. 5166 H.R. 5258 H.R. 5270 H.R. 5408 H.R. 5437 H.R. 5463 H.R. 5484 H.R. 5494 H.R. 5551 H.R. 5631 H.R. 5689 H.R. 5764 H.R. 5784 H.R. 5926 H.R. 6055 H.R. 6084 H.R. 6129 H.R. 6194 H.R. 6294 H.R. 6333 H.R. 6336 H.R. 6373 H.R. 6387 H.R. 6398 H.R. 6409 H.R. 6453 H.R. 6461 H.R. 6484 H.R. 6500 H.R. 6504 H.R. 6553 H.R. 6623 H.R. 6644 H.R. 6955 H.R. 7023 H.R. 7056 H.R. 7084 H.R. 7085 H.R. 7127 H.R. 7128 H.R. 7257 H.R. 7258 H.R. 7266 H.R. 7291 H.R. 7305 H.R. 7390 H.R. 7450 H.R. 7502 H.R. 7567 H.R. 7688 H.R. 7845 H.R. 8013 H.R. 8045 H.R. 8101 H.R. 8183 H.R. 8210 H.R. 8286 H.R. 8324 H.R. 8338 H.R. 8389 H.R. 8413 H.R. 8477 H.R. 8624 H.R. 8673 H.R. 8714 H.R. 8780 H.R. 8790 H.R. 8800 H.R. 8870 H.R. 9194 H.R. 9224 H.R. 9238 H.R. 9250 H.R. 9310 H.R. 9317 S. 199 S. 351 S. 424 S. 492 S. 495 S. 577 S. 714 S. 796 S. 844 S. 985 S. 1071 S. 1241 S. 1323 S. 1367 S. 1404 S. 1462 S. 1596 S. 1686 S. 1705 S. 1748 S. 1808 S. 1839 S. 1843 S. 1847 S. 1877 S. 2228 S. 2260 S. 2296 S. 2511 S. 2651 S. 2658 S. 2714 S. 2827 S. 2828 S. 2875 S. 2924 S. 2934 S. 3122 S. 3170 S. 3180 S. 3305 S. 3332 S. 3404 S. 3578 S. 3605 S. 3671 S. 3800 S. 3808 S. 3822 S. 3826 S. 3841 S. 3931 S. 3947 S. 3967 S. 3971 S. 4007 S. 4016 S. 4055 S. 4071 S. 4217 S. 4221 S. 4360 S. 4463 S. 4506 S. 4615 S. 4639 S. 4746 S. 4753 S. 4784 S. 4815 S. 4850 S. 5139 S.Con.Res. 14 S.J.Res. 11 S.J.Res. 12 S.J.Res. 18 S.J.Res. 28 S.J.Res. 36 S.J.Res. 45 S.J.Res. 46 S.J.Res. 47 S.J.Res. 55

Lobbying reported · Fresenius Kabi USA · Jul 20

Fresenius Kabi USA reported 2nd Quarter (Apr 1 - June 30) lobbying for Fresenius Kabi USA — $580,000

BillsH.R. 3269 H.R. 5526 S. 1414 S. 1954 S. 2658

Lobbying reported · Blood Cancer United · Jul 20

Blood Cancer United reported 2nd Quarter (Apr 1 - June 30) lobbying for Blood Cancer United — $590,000

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · Johnson & Johnson Services · Jul 20

Johnson & Johnson Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $1,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Small Business & Entrepreneurship Council (SBE Council) · Jul 20

Small Business & Entrepreneurship Council (SBE Council) reported 2nd Quarter (Apr 1 - June 30) lobbying for Small Business & Entrepreneurship Council (SBE Council) — $45,000

Lobbying reported · Incyte · Jul 20

Incyte reported 2nd Quarter (Apr 1 - June 30) lobbying for Incyte — $750,000

BillsH.Res. 1331 S. 2658

Lobbying reported · Eisai · Jul 20

Eisai reported 2nd Quarter (Apr 1 - June 30) lobbying for Eisai — $790,000

BillsH.R. 1 H.R. 3747 H.R. 4752 H.R. 6130 S. 2379 S. 2658 S. 3267

Lobbying reported · American Society Of Health-System Pharmacists · Jul 20

American Society Of Health-System Pharmacists reported 2nd Quarter (Apr 1 - June 30) lobbying for American Society Of Health-System Pharmacists — $260,000

Lobbying reported · Pfizer · Jul 20

Pfizer reported 2nd Quarter (Apr 1 - June 30) lobbying for Pfizer — $1,880,000

BillsH.Con.Res. 14 H.R. 1 H.R. 4299 H.R. 4930 H.R. 5178 H.R. 5526 H.R. 7391 H.R. 7837 H.R. 8646 H.R. 9102 H.R. 9260 S. 2658